Retina

The drug has been reported previously to cause neuropathy and hypersensitivity reactions in breast cancer patients.

Dilraj S. Grewal, MD, FASRS, provides an in-depth overview of the current state of research and treatment innovations.

This partnership aims to address care gaps by identifying untreated and undertreated patients at scale.

Sunir Garg, MD, discusses a challenge in ophthalmological procedures: patient discomfort during intravitreal injections caused by povidone iodine.

The new surgical technique incorporates a new surgical clamp that maintains eye pressure during the insertion of 2 tissue patches in immediate succession while minimizing damage to the surrounding tissue.

ABCA4-associated retinopathies include Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

Swedish researchers reveal that vitamins B6, B9, B12, and choline offer neuroprotection against glaucoma, highlighting potential new treatment avenues.

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months

The designation is based off previously reported phase 3 data from the ongoing DRAGON trial.

Kapil Mishra, MD, discusses his presentation title "Radiation Retinopathy: Future Strategies" given at the 2025 Retina World Congress meeting.

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

By making these retinal pigment epithelium (RPE) cells visible, researchers have created implications for early detection of disease and the monitoring of treatment response.

AAVantgarde Bio reveals promising safety and efficacy data for AAV-based therapies targeting Usher syndrome and Stargardt disease at ARVO 2025.

Palatin Technologies reveals groundbreaking preclinical results on melanocortin agonists, showcasing their potential to combat diabetic retinopathy and preserve vision.

New research reveals how low blood sugar can damage the retina in diabetes, highlighting potential treatments targeting specific proteins to prevent vision loss.

In this conversation, Franklin discussed a research study on intraoperative fluorescein angiography in surgical procedures, highlighting significant advancements in surgical visualization and patient outcomes.

Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in XLRP patients.

Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads.

The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.

Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in healthcare.

The trial will assess allogeneic retinal pigment epithelium cells in the treatment of geographic atrophy.

In this Q&A, Luke Lindsell, OD, MD, shares his insights on emerging therapies in retina, the evolving role of optometrists in retinal disease management, and the importance of comanagement in patient care.

Opus Genetics reveals promising 1-year results from OPGx-LCA5 gene therapy, showing sustained vision improvements in adults with LCA5 retinal degeneration.

New research reveals subretinal drusenoid deposits as potential indicators of serious heart disease, highlighting the need for ophthalmologists to screen patients effectively.

Researchers stratified a dataset of more than 100 patients in an emergency department to see which patients may be indicated for retinal artery occlusions.

At the ARVO 2025 meeting in Salt Lake City, Utah, Cameron Cummings presented a poster on how retinal microvascular imaging metrics may show sex-specific biomarkers for Parkinson's disease.